Does using applied muscle tension at strategic time points during donation reduce phlebotomist- and donor-reported vasovagal reaction rates? A three-armed randomized controlled trial

Transfusion ◽  
2018 ◽  
Vol 58 (10) ◽  
pp. 2352-2359 ◽  
Author(s):  
Amanda Thijsen ◽  
Carley N. Gemelli ◽  
Tanya E. Davison ◽  
Justine O'Donovan ◽  
Barbara Bell ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Controlled Trial ◽  
Muscle Tension ◽  
Reaction Rates ◽  
Time Points ◽  
Vasovagal Reaction ◽  
Randomized Controlled ◽  
Applied Muscle Tension

Reducing reactions to blood donation with applied muscle tension: a randomized controlled trial

Transfusion ◽  
2003 ◽  
Vol 43 (9) ◽  
pp. 1269-1276 ◽  
Author(s):  
Blaine Ditto ◽  
Christopher R. France ◽  
Pauline Lavoie ◽  
Marios Roussos ◽  
Perry S.J. Adler
Keyword(s):  
Randomized Controlled Trial ◽  
Blood Donation ◽  
Controlled Trial ◽  
Muscle Tension ◽  
Randomized Controlled ◽  
Applied Muscle Tension

Randomized controlled trial of vertebroplasty versus kyphoplasty in the treatment of vertebral compression fractures

2015 ◽  
Vol 8 (7) ◽  
pp. 756-763 ◽  
Author(s):  
Avery J Evans ◽  
Kevin E Kip ◽  
Waleed Brinjikji ◽  
Kennith F Layton ◽  
Mary L Jensen ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Vertebral Body ◽  
Controlled Trial ◽  
Vertebral Compression Fractures ◽  
Compression Fractures ◽  
Time Points ◽  
Randomized Controlled ◽  
Primary Endpoints ◽  
Average Pain ◽  
Registration Number

BackgroundWe present the results of a randomized controlled trial evaluating the efficacy of vertebroplasty versus kyphoplasty in treating vertebral body compression fractures.MethodsPatients with vertebral body compression fractures were randomly assigned to treatment with kyphoplasty or vertebroplasty. Primary endpoints were pain (0–10 scale) and disability assessed using the Roland–Morris Disability Questionnaire (RMDQ). Outcomes were assessed at 3 days, 1 month, 6 months, and 1 year following the procedure.Results115 subjects were enrolled in the trial with 59 (51.3%) randomly assigned to kyphoplasty and 56 (48.7%) assigned to vertebroplasty. Mean (SD) pain scores at baseline, 3 days, 30 days, and 1 year for kyphoplasty versus vertebroplasty were 7.4 (1.9) vs 7.9 (2.0), 4.1 (2.8) vs 3.7 (3.0), 3.4 (2.5) vs 3.6 (2.9), and 3.0 (2.8) vs 2.3 (2.6), respectively (p>0.05 at all time points). Mean (SD) RMDQ scores at baseline, 3 days, 30 days, 180 days, and 1 year were 17.3 (6.6) vs 16.3 (7.4), 11.8 (7.9) vs 10.9 (8.2), 8.6 (7.2) vs 8.8 (8.5), 7.9 (7.4) vs 7.3 (7.7), 7.5 (7.2) vs 6.7 (8.0), respectively (p>0.05 at all time points). For baseline to 12-month assessment in average pain and RMDQ scores, the standardized effect size between kyphoplasty and vertebroplasty was small at −0.36 (95% CI −1.02 to 0.31) and −0.04 (95% CI −1.68 to 1.60), respectively.ConclusionsOur study indicates that vertebroplasty and kyphoplasty appear to be equally effective in substantially reducing pain and disability in patients with vertebral body compression fractures.Trial registration numberNCT00279877.

scholarly journals Comparison of Intravenous Lidocaine and Dexmedetomidine Infusion for Prevention of Postoperative Catheter-Related Bladder Discomfort: A Randomized Controlled Trial

2018 ◽  
Author(s):  
Shuying Li ◽  
Hui Li ◽  
Juan Ni ◽  
Yushan Ma
Keyword(s):  
Randomized Controlled Trial ◽  
Controlled Trial ◽  
Abdominal Hysterectomy ◽  
Urinary Catheterization ◽  
Intravenous Lidocaine ◽  
Time Points ◽  
Randomized Controlled ◽  
Significant Difference ◽  
Group D ◽  
Dexmedetomidine Infusion

Abstract Background: Catheter-related bladder discomfort (CRBD) frequently occurs during recovery in patients who undergo intra-operative urinary catheterization distress. We conducted this study to compare the effect of intravenous lidocaine and dexmedetomidine infusion for preventing CRBD. Methods: 120 patients undergoing elective open abdominal hysterectomy and hysteromyoma requiring urinary bladder catheterization were randomly allocated into three groups of 40 each. Group L received a 2 mg/kg lidocaine bolus followed by infusion of 1.5 mg/kg/h; Group D received a 0.5 mg/kg dexmedetomidine bolus followed by infusion of 0.4 mg/kg/h; Group C received a bolus and infusion of normal saline of equivalent volume. The incidence and different severity (mild, moderate, and severe) of CRBD were assessed on arrival in the postanaesthesia care unit at 0, 1, 2, and 6 h postoperatively. Results: The incidence of CRBD was significantly lower in Group L and Group D compared with Group C at 0, 1, and 2 h. However, there was no significant difference among the three groups regarding the different severity of CRBD at all time points. The requirement of rescue tramadol for CRBD was lower in group L and group D than in group C. The incidence of sedation was significantly higher in Group D compared to Group L and Group C, though no difference in other adverse effects was observed. Conclusions: Intravenous lidocaine and dexmedetomidine infusion reduced the incidence of CRBD as well as the additional tramadol requirement for CRBD, but had no effect on the different severity of CRBD.

scholarly journals Effect of “Deqi” during the Study of Needling “Wang’s Jiaji” Acupoints Treating Spasticity after Stroke

2014 ◽  
Vol 2014 ◽  
pp. 1-8 ◽  
Author(s):  
Huanqin Li ◽  
Huilin Liu ◽  
Cunzhi Liu ◽  
Guangxia Shi ◽  
Wei Zhou ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Statistical Difference ◽  
Early Stage ◽  
Controlled Trial ◽  
Muscle Tension ◽  
Sham Acupuncture ◽  
Acupuncture Group ◽  
Randomized Controlled ◽  
Prospective Randomized Controlled Trial ◽  
Sham Acupuncture Group

Background.Acupuncture has been shown to reduce spasticity and prevent the onset of spasticity after stroke. The purpose of this study is to assess the effect of “Deqi” during needling “Wang’s Jiaji” acupoints treating spasticity in the early stage of stroke.Methods. This study is a multicenter, prospective, randomized, controlled trial. 238 patients with stroke (<21 days) participated and were randomly allocated to the verum-acupuncture (n=121) group or sham-acupuncture group (n=117). The verum-acupuncture group received verum acupuncture required to produce the sense of “Deqi” while the sham-acupuncture group received sham acupuncture without “Deqi.” Patients in both groups followed the same 30 min acupuncture regimen 5 times per week for a period of 4 weeks. Scales of MAS, FMA, ADL, MBI, NIHSS, SS-QOL, and MRS were measured at baseline and at 2, 4, and 12 weeks after intervention.Results.Significant differences were observed between two groups. The MRS rating composition has the statistical difference after 4 weeks (P=0.017). The score of MAS, FMA, Barthel, and SSQOL in verum-acupuncture group has increased significantly compared with the sham-acupuncture group after 12 weeks. There was 14% reduction of higher muscle tension in the verum-acupuncture group.Conclusion.Acupuncture “Wang’s Jiaji” points with sensation of “Deqi” in the early stage may reduce the occurrence and decrease the severity of spasticity after stroke.

scholarly journals Comparison of Intravenous Lidocaine and Dexmedetomidine Infusion for Prevention of Postoperative Catheter-Related Bladder Discomfort: A Randomized Controlled Trial

2019 ◽  
Author(s):  
Shuying Li ◽  
Hui Li ◽  
Juan Ni ◽  
YuShan Ma
Keyword(s):  
Randomized Controlled Trial ◽  
Controlled Trial ◽  
Abdominal Hysterectomy ◽  
Urinary Catheterization ◽  
Intravenous Lidocaine ◽  
Time Points ◽  
Randomized Controlled ◽  
Significant Difference ◽  
Group D ◽  
Dexmedetomidine Infusion

Abstract Background Catheter-related bladder discomfort (CRBD) frequently occurs during recovery in patients who undergo intra-operative urinary catheterization distress. We conducted this study to compare the effect of intravenous lidocaine and dexmedetomidine infusion for preventing CRBD. Methods 120 patients undergoing elective open abdominal hysterectomy and hysteromyoma requiring urinary bladder catheterization were randomly allocated into three groups of 40 each. Group L received a 2 mg/kg lidocaine bolus followed by infusion of 1.5 mg/kg/h; Group D received a 0.5 mg/kg dexmedetomidine bolus followed by infusion of 0.4 mg/kg/h; Group C received a bolus and infusion of normal saline of equivalent volume. The incidence and different severity (mild, moderate, and severe) of CRBD were assessed on arrival in the postanaesthesia care unit at 0, 1, 2, and 6 h postoperatively. Results The incidence of CRBD was significantly lower in Group L and Group D compared with Group C at 0, 1, and 2 h. However, there was no significant difference among the three groups regarding the different severity of CRBD at all time points. The requirement of rescue tramadol for CRBD was lower in group L and group D than in group C. The incidence of sedation was significantly higher in Group D compared to Group L and Group C, though no difference in other adverse effects was observed. Conclusions Intravenous lidocaine and dexmedetomidine infusion reduced the incidence of CRBD as well as the additional tramadol requirement for CRBD, but had no effect on the different severity of CRBD.

A randomized controlled trial of stretch-and-flow voice therapy for muscle tension Dysphonia

2015 ◽  
Vol 125 (6) ◽  
pp. 1420-1425 ◽  
Author(s):  
Christopher R. Watts ◽  
Amy Hamilton ◽  
Laura Toles ◽  
Lesley Childs ◽  
Ted Mau
Keyword(s):  
Randomized Controlled Trial ◽  
Controlled Trial ◽  
Muscle Tension ◽  
Voice Therapy ◽  
Muscle Tension Dysphonia ◽  
Randomized Controlled

scholarly journals Moxibustion for Patients with Primary Dysmenorrhea at Different Intervention Time Points: A Randomized Controlled Trial

2020 ◽  
Vol Volume 13 ◽  
pp. 2653-2662
Author(s):  
Li-ying Liu ◽  
Xiao-ji Li ◽  
Wei Wei ◽  
Xiao-li Guo ◽  
Li-hua Zhu ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Controlled Trial ◽  
Primary Dysmenorrhea ◽  
Time Points ◽  
Randomized Controlled

scholarly journals Long-Term Follow-up from the Treatment and Crossover Arms of a Randomized Controlled Trial of an Absorbable Nasal Implant for Dynamic Nasal Valve Collapse

2021 ◽  
Author(s):  
Nadim Bikhazi ◽  
Randall A. Ow ◽  
Ellen M. O'Malley ◽  
Nora Perkins ◽  
Douglas M. Sidle ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Adverse Events ◽  
Controlled Trial ◽  
Nasal Valve ◽  
Time Points ◽  
Randomized Controlled ◽  
Nasal Implant ◽  
Nasal Valve Collapse

AbstractWe report the long-term safety and efficacy outcomes of the treatment and crossover arms of a randomized controlled trial evaluating an absorbable nasal implant to address dynamic nasal valve collapse. Participants were adults with severe/extreme nasal airway obstruction primarily due to nasal valve insufficiency who had implant placement. Follow-up visits were at 3, 6, 12, 18, and 24 months post implant. Visits included collection of the following patient-reported outcome measures: nasal obstructive symptom evaluation (NOSE), nasal obstruction visual analog scale (VAS), and the Epworth Sleepiness Scale (ESS). Adverse events were evaluated at each visit. One-hundred-eleven participants with implants were followed. Of the 111, 90 completed the 12-month visit and 70 completed the 24-month visit. NOSE responder rates are greater than 80% at all follow-ups through 24 months. Mean reduction from baseline in NOSE scores is ≥30 points and statistically significant (p <0.001) at all time points through 24 months. Mean VAS score reduction is ≥29.7 points and statistically significant (p <0.001) at all time points. The subgroup of participants with baseline ESS values >10 experienced statistically significant (p <0.001) and clinically meaningful reductions at all postimplant periods, suggesting that the reduction in nasal symptoms may reduce daytime sleepiness for patients who have problems with sleep quality. No serious device-/procedure-related adverse events were reported. Implant migration/retrieval rate was 4.5% (10/222) of total implants or 9% of participants (10/111). The implant is safe and effective for dynamic nasal valve collapse in patients with severe/extreme nasal obstruction and provides durable symptom improvement 24 months after placement.

scholarly journals Exploring the effects of cognitive remediation on metacognition in people with schizophrenia

2019 ◽  
Vol 10 (2) ◽  
pp. 204380871982684 ◽  
Author(s):  
Matteo Cella ◽  
Clementine Edwards ◽  
Sarah Swan ◽  
Kay Elliot ◽  
Clare Reeder ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Controlled Trial ◽  
Cognitive Remediation ◽  
The Novel ◽  
Valid Measure ◽  
Cognitive Measures ◽  
Treatment As Usual ◽  
Systematic Assessment ◽  
Time Points ◽  
Randomized Controlled

Background: Interventions targeting cognition in people with schizophrenia have shown moderate effects on improving functioning. Recent cognitive remediation (CR) approaches have begun to target metacognition to improve functioning outcomes. This study aims to develop a novel measure of metacognition and assess whether metacognitive-based CR (mCR) can improve metacognition. Method: We use data from a single-blinded randomized controlled trial comparing mCR plus treatment as usual (TAU) to TAU alone in people with schizophrenia. Participants were assessed with measures of cognition, functioning, and a new measure of metacognition at three time points: Week 0 (baseline), Week 12, and Week 24. Results: The evaluation of the novel metacognition assessment suggests that it is a reliable and valid measure. The measure positively correlates with cognitive measures, in particular with executive function and IQ but also with a measure of functioning. We found that a course of mCR was able to increase metacognition compared to TAU by Week 24. Conclusions: Metacognition may be an important mechanism to explain how CR affects functioning outcomes in people with psychosis. The systematic assessment of metacognition as part of CR studies may help to evaluate more clearly its role and relevance to functioning.

Sign in / Sign up

Export Citation Format

Share Document